• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 24, 2013

View Archived Issues

Amgen Beats 3Q Estimates; Long-Term Growth is Key

Amgen Inc. posted higher-than-expected third quarter earnings, thanks in large part to a hefty one-time government purchase of Neupogen (filgrastim). That contract, combined with anticipated revenues from recently acquired Onyx Pharmaceuticals Inc., prompted the Thousand Oaks, Calif.-based biotech to bump up its revenue guidance for the year but fell short of distracting investors and analysts away from long-term plans for growth. Read More

Basilea Shares Rise As Ceftobiprole Snags EU Approval

Shares in Basilea Pharmaceutica AG rose more than 7 percent Wednesday on news that its broad spectrum cephalosporin antibiotic ceftobiprole gained approval in Europe for treating hospital- and community-acquired pneumonia in adults. The company is still on the hunt for a commercialization partner, however, and the drug will not reach the market until next year. Read More

Gilead’s Sofosbuvir Expected to Sail Through Panel Meeting

FDA briefing documents appear to be positive in advance of a meeting of the FDA Antiviral Drugs Advisory Committee scheduled for Friday to discuss approval of sofosbuvir in hepatitis C virus (HCV). Questions for the panelists focus on optimal duration of therapy in genotype 2 and 3 patients. The FDA’s documents suggest that the agency is favorably inclined toward approval of the drug, and sees no significant safety issues with it. Read More

Global Standards Needed for Sharing of Trial Data

The question is no longer should clinical trial data be shared but, rather, how can it best be shared. Hoping to answer that question, an Institute of Medicine (IOM) committee heard from a range of experts Wednesday on strategies to responsibly share raw trial data. Read More

Study Decodes Circadian Liver Signaling to Muscle

Scientists have identified a key signaling molecule that the liver uses to influence muscle metabolism, and shown that such signaling has its own circadian rhythms. Read More

Other News To Note

• Lorus Therapeutics Inc., of Toronto, said that it has received court approval to delay its Annual General Meeting to a date no later than March 31, 2013. Read More

Financings Roundup

• Ziopharm Oncology Inc., of Boston, said it intends to commence an underwritten public offering of $50 million shares of its common stock. J.P. Morgan Securities LLC will act as sole book-running manager for the proposed offering and the company intends to grant the underwriters a 30-day option to purchase up to $7.5 million of additional shares. Read More

Clinic Roundup

• Halozyme Therapeutics Inc., of San Diego, Calif., began a Phase Ib/II trial of PEGPH20 in combination with FOLFIRINOX chemotherapy compared to FOLFIRINOX alone in metastatic pancreatic adenocarcinoma. The trial will enroll about 144 patients. The initial Phase Ib portion of the trial will confirm the optimal dose of PEGPH20 for the Phase II potion, which will evaluate overall survival. Secondary endpoints include progression-free survival, objective tumor response, and adverse events. Read More

Appointments and Advancements

• Novelos Therapeutics, Inc., of Madison, Wis., named Simon Pedder acting CEO. Read More

Pharma: Other News To Note

• Merck & Co. Inc., of Whitehouse Station, N.J., said the FDA granted MK-5172/MK-8742 breakthrough therapy designation for treatment of chronic hepatitis C virus infection. MK-5172/MK-8742 is an all-oral combination regimen consisting of MK-5172, an investigational HCV NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor. Interim data from an ongoing Phase IIb clinical trial evaluating MK-5172/MK-8742 in genotype 1 infected patients (C-WORTHY Study) is scheduled to be presented at the 64th American Association for the Study of Liver Disease Annual Meeting in November. Read More

Stock Movers

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • 3D heart in chest

    At CRVBC 2025: Aging is circulating in your blood

    BioWorld Science
    All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins,...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe